Stoke Therapeutics Inc. (STOK)
$30.19
$-0.71
(-2.28%)
As on 02-Sep-2026 11:34EDT
Market cap
$2,040 Mln
Revenue (TTM)
$28 Mln
P/E Ratio
--
P/B Ratio
6.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
52.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.4
-
Face value
--
-
Shares outstanding
64,526,242
7 Years Aggregate
CFO
$-269.46 Mln
EBITDA
$-403.34 Mln
Net Profit
$-379.73 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
| -4.9 | 4.6 | -0.9 | 52.8 | 76.0 | 2.6 | -- |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
| 187.8 | 108.4 | -43.0 | -61.5 | -61.3 | 118.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Stoke Therapeutics (STOK)
|
30.2 | 2,040.3 | 27.6 | -207.9 | -759.7 | -59.6 | -- | 6.1 |
| 82.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.7 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 57.3 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 108.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 365.7 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 349.9 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 145.0 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Stoke Therapeutics (STOK)
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing... antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Read more
-
CEO & Director
Dr. Edward M. Kaye M.D., Ph.D.
-
CEO & Director
Dr. Edward M. Kaye M.D., Ph.D.
-
Headquarters
Bedford, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Stoke Therapeutics (STOK)
What is the current share price of Stoke Therapeutics Inc (STOK) Today?
The share price of Stoke Therapeutics Inc (STOK) is $30.19 (NASDAQ) as of 02-Sep-2026 11:34 EDT. Stoke Therapeutics Inc (STOK) has given a return of 75.97% in the last 3 years.
What is the current PB & PE ratio of Stoke Therapeutics Inc (STOK)?
Since, TTM earnings of Stoke Therapeutics Inc (STOK) is negative, P/E ratio is not available.
The P/B ratio of Stoke Therapeutics Inc (STOK) is 6.09 times as on 28-Aug-2026, a 18 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-269.17 |
5.26 |
2024 |
-7.07 |
2.75 |
2023 |
-2.26 |
1.48 |
2022 |
-3.91 |
1.97 |
2021 |
-10.43 |
4.06 |
What is the 52 Week High and Low of Stoke Therapeutics Inc (STOK)?
The 52-week high and low of Stoke Therapeutics Inc (STOK) are Rs 40.22 and Rs 19.11 as of 02-Sep-2026.
What is the market cap of Stoke Therapeutics Inc (STOK)?
Stoke Therapeutics Inc (STOK) has a market capitalisation of $ 2,040 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Stoke Therapeutics Inc (STOK)?
Before investing in Stoke Therapeutics Inc (STOK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.